{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:47:02Z","timestamp":1777434422599,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>\nIntroduction.<\/jats:italic>\u00a0The combination of BRAF and MEK inhibitors has deeply changed the treatment of <jats:italic>BRAF V600-<\/jats:italic>mutant non-small cell lung cancer patients. These agents demonstrated high antitumor activity as well as safe and manageable toxicity profile. Hypertension, pyrexia and increased liver enzymes are the most common adverse events. Gastrointestinal toxicities are rare, and mainly consist of mild grade vomiting and diarrhea. <jats:italic>Case report<\/jats:italic>.\u00a0We report the case of 70-year-old man affected by <jats:italic>BRAF V600<\/jats:italic>-mutant NSCLC with bilateral lung and bone metastases. First-line treatment with encorafenib (450\u00a0mg once daily) and binimetinib (45\u00a0mg twice daily) was administered within a clinical trial. At the first radiological assessment, computed tomography (CT) scan showed a partial response and signs of intestinal inflammation were reported. The investigational treatment was timely withheld. The subsequent colonoscopy demonstrated the presence of ulcerative lesions at the caecal tract, and the histological diagnosis suggested a drug-induced colitis. No specific treatment was given as the patient did not report abdominal disturbances. Forty-five days after treatment interruption a new CT scan showed the resolution of bowel inflammation and investigational treatment was resumed at the same doses. The patient is still alive and free of toxicity recurrence after 11\u00a0months from treatment initiation.\u00a0<jats:italic>Conclusion<\/jats:italic>. Severe gastrointestinal toxicities are uncommon with BRAF and MEK inhibitors, although cases of colitis and intestinal perforation have already been reported in literature. The pathogenesis seems to be related to the MAPK pathway inhibition performed by MEK inhibitors. These adverse events should be accounted given the potential to evolve into life-threatening conditions.<\/jats:p>","DOI":"10.1007\/s10637-021-01166-7","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T07:02:56Z","timestamp":1629961376000},"page":"190-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-1728","authenticated-orcid":false,"given":"Francesco","family":"Gelsomino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Di Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lucia","family":"Tardio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giada","family":"Grilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"D\u2019Errico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Salvagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"1166_CR1","doi-asserted-by":"crossref","unstructured":"Barlesi F, Mazieres J, Merlio JP et al (2016) for the Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 3871415\u201326","DOI":"10.1016\/S0140-6736(16)00004-0"},{"key":"1166_CR2","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","volume":"29","author":"PK Paik","year":"2011","unstructured":"Paik PK, Arcila ME, Fara M et al (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046\u20132051","journal-title":"J Clin Oncol"},{"issue":"10","key":"1166_CR3","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM et al (2017) Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 18(10):1307\u20131316","journal-title":"Lancet Oncol"},{"key":"1166_CR4","doi-asserted-by":"publisher","unstructured":"Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984\u2013993. Epub 2016 Jun 6. PMID: 27283860; PMCID: PMC4993103. https:\/\/doi.org\/10.1016\/S1470-2045(16)30146-2","DOI":"10.1016\/S1470-2045(16)30146-2"},{"issue":"3","key":"1166_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C et al (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14(3):249\u2013256. https:\/\/doi.org\/10.1016\/S1470-2045(13)70024-X","journal-title":"Lancet Oncol"},{"issue":"5","key":"1166_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/CMR.0000000000000618","volume":"29","author":"N Mourad","year":"2019","unstructured":"Mourad N, Louren\u00e7o N, Delyon J et al (2019) Severe gastrointestinal toxicity of MEK inhibitors. Melanoma Res 29(5):556\u2013559. https:\/\/doi.org\/10.1097\/CMR.0000000000000618","journal-title":"Melanoma Res"},{"key":"1166_CR7","doi-asserted-by":"publisher","unstructured":"Kass SL, Linden AF, Jackson PG, De Brito PA, Atkins MB (2015) Bowel perforation associated with robust response to BRAF\/MEK inhibitor therapy for BRAF-mutant melanoma: a case report. Melanoma Manag 2:115\u2013120. https:\/\/doi.org\/10.2217\/mmt.15.10","DOI":"10.2217\/mmt.15.10"},{"key":"1166_CR8","doi-asserted-by":"publisher","unstructured":"Uppaluri R, Winkler AE, Lin T et al (2017) Biomarker and tumor responses of oral cavity squamous cell carcinoma to trametinib: a phase II neoadjuvant window-of-opportunity clinical trial. Clin Cancer Res 23:2186\u20132194. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1469","DOI":"10.1158\/1078-0432.CCR-16-1469"},{"key":"1166_CR9","doi-asserted-by":"publisher","unstructured":"Shimada Y, Sato Y, Tachikawa R, Hara S, Tomii K (2021) Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review [published online ahead of print, 2021 May 23]. Invest New Drugs. https:\/\/doi.org\/10.1007\/s10637-021-01135-0","DOI":"10.1007\/s10637-021-01135-0"},{"key":"1166_CR10","doi-asserted-by":"publisher","first-page":"10143","DOI":"10.3390\/ijms140510143","volume":"14","author":"LH Osaki","year":"2013","unstructured":"Osaki LH, Gama P (2013) MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci 14:10143\u201310161","journal-title":"Int J Mol Sci"},{"key":"1166_CR11","doi-asserted-by":"publisher","unstructured":"Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y (2019) Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. Cancers (Basel). 2019;11(12):1950. Published 2019 Dec 5. https:\/\/doi.org\/10.3390\/cancers11121950","DOI":"10.3390\/cancers11121950"},{"key":"1166_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejca.2018.06.030","volume":"101","author":"G Ben-Betzalel","year":"2018","unstructured":"Ben-Betzalel G, Baruch EN, Boursi B et al (2018) Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Eur J Cancer 101:229\u2013235. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.030","journal-title":"Eur J Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01166-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01166-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01166-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:38:53Z","timestamp":1678509533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01166-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1166"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01166-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]},"assertion":[{"value":"26 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The patient declared to consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patient declared to consent to the publication of the current paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Francesco Gelsomino received honoraria for advisory board participation: Eli-Lilly. Andrea Ardizzoni received honoraria for advisory board participation: BMS, MSD, ROCHE, Astra Zeneca, Eli-Lilly. Research Grants: Celgene, BMS, Ipsen, Roche. All remaining authors have declared no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}